Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Nicole DeFeudis

Editor

Michael Heffernan was already the head of a biotech company focused on chronic pain, called Collegium Pharmaceutical, which he successfully brought public in 2015. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Tak­ing notes from MD An­der­son and Rice Uni­ver­si­ty, Avenge Bio un­cloaks with $45M and a slate of im­munother­a­pies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?